Total Payments
$454,847
2024 Payments
$1,687
Companies
84
Transactions
736
Medicare Patients
15,011
Medicare Billing
$3.1M
Payment Breakdown by Category
Research$385,743 (84.8%)
Consulting$43,163 (9.5%)
Food & Beverage$14,012 (3.1%)
Travel$8,357 (1.8%)
Other$3,450 (0.8%)
Education$121.42 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $385,743 | 58 | 84.8% |
| Consulting Fee | $43,163 | 19 | 9.5% |
| Food and Beverage | $14,012 | 619 | 3.1% |
| Travel and Lodging | $8,357 | 34 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,450 | 1 | 0.5% |
| Honoraria | $1,000 | 1 | 0.2% |
| Education | $121.42 | 4 | 0.0% |
Payments by Type
Research
$385,743
58 transactions
General
$69,104
678 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Spectrum Pharmaceuticals Inc. | $383,474 | 57 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $13,087 | 57 | $0 (2024) |
| Celgene Corporation | $11,608 | 54 | $0 (2024) |
| Genentech, Inc. | $5,572 | 4 | $0 (2023) |
| PFIZER INC. | $5,461 | 51 | $0 (2024) |
| Exelixis Inc. | $3,853 | 17 | $0 (2024) |
| INSYS Therapeutics Inc | $3,566 | 2 | $0 (2017) |
| GlaxoSmithKline, LLC. | $3,355 | 16 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,409 | 8 | $0 (2023) |
| GENZYME CORPORATION | $2,051 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,687 | 73 | AstraZeneca Pharmaceuticals LP ($225.60) |
| 2023 | $9,896 | 142 | Genentech, Inc. ($5,572) |
| 2022 | $3,424 | 101 | BeiGene USA, Inc. ($1,368) |
| 2021 | $5,381 | 67 | Kite Pharma, Inc. ($1,726) |
| 2020 | $9,768 | 33 | PFIZER INC. ($4,753) |
| 2019 | $7,689 | 78 | Spectrum Pharmaceuticals Inc. ($3,992) |
| 2018 | $401,344 | 151 | Spectrum Pharmaceuticals Inc. ($379,465) |
| 2017 | $15,658 | 91 | AstraZeneca Pharmaceuticals LP ($5,224) |
All Payment Transactions
736 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $7.63 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $1.61 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: HEMATOLOGY | ||||||
| 08/01/2024 | Spectrum Pharmaceuticals Inc. | ROLVEDON (Drug) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Oncology | ||||||
| 07/10/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $26.08 | General |
| Category: ONCOLOGY | ||||||
| 06/25/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $23.91 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 06/19/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $14.59 | General |
| 06/13/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Cumberland Pharmaceuticals, Inc. | SANCUSO (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: ONCOLOGY | ||||||
| 06/07/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $38.74 | General |
| 06/05/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: Oncology | ||||||
| 06/04/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $34.20 | General |
| Category: ONCOLOGY | ||||||
| 05/28/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $22.55 | General |
| Category: Hematology | ||||||
| 05/15/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Oncology | ||||||
| 05/09/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA, TECVAYLI | Food and Beverage | In-kind items and services | $27.29 | General |
| Category: Oncology | ||||||
| 05/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.79 | General |
| 05/06/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $34.37 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 04/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.27 | General |
| 04/17/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| SPI-GCF-301 | Spectrum Pharmaceuticals Inc. | $278,916 | 39 |
| SPI-GCF-302 | Spectrum Pharmaceuticals Inc. | $85,518 | 9 |
| SPI-POZ-101 | Spectrum Pharmaceuticals Inc. | $13,214 | 5 |
| SPI-POZ-201 | Spectrum Pharmaceuticals Inc. | $5,500 | 1 |
| TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | Takeda Pharmaceuticals U.S.A., Inc. | $2,295 | 3 |
| SPI-GCF-301PK | Spectrum Pharmaceuticals Inc. | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 3,511 | 71,982 | $1.8M | $690,991 |
| 2022 | 40 | 3,640 | 83,406 | $1.9M | $731,221 |
| 2021 | 38 | 3,745 | 76,890 | $1.7M | $776,559 |
| 2020 | 48 | 4,115 | 145,965 | $2.2M | $926,144 |
Total Patients
15,011
Total Services
378,243
Medicare Billing
$3.1M
Procedure Codes
166
All Medicare Procedures & Services
166 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 476 | 2,035 | $407,540 | $218,571 | 53.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 66 | 9,420 | $471,000 | $173,999 | 36.9% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 454 | 659 | $98,850 | $44,915 | 45.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 210 | 295 | $77,080 | $44,546 | 57.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 118 | 214 | $39,590 | $22,671 | 57.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 45 | 48,960 | $244,800 | $19,143 | 7.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 20 | 136 | $54,400 | $16,702 | 30.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 437 | 1,880 | $18,800 | $15,784 | 84.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 104 | 198 | $29,683 | $15,637 | 52.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 82 | 82 | $31,324 | $15,060 | 48.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 434 | 1,960 | $88,200 | $14,909 | 16.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 90 | 238 | $35,700 | $14,104 | 39.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 30 | 397 | $23,820 | $10,632 | 44.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 55 | 83 | $12,450 | $8,468 | 68.0% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 119 | 170 | $13,940 | $8,150 | 58.5% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 114 | 168 | $15,288 | $7,958 | 52.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 169 | 590 | $23,600 | $7,402 | 31.4% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 17 | 815 | $20,375 | $4,886 | 24.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 28 | $7,700 | $4,164 | 54.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 39 | 45 | $5,895 | $3,526 | 59.8% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 12 | 553 | $8,295 | $3,327 | 40.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 41 | 42 | $3,360 | $3,014 | 89.7% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 13 | 77 | $6,160 | $2,282 | 37.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 74 | $5,920 | $1,905 | 32.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 13 | 81 | $2,592 | $1,527 | 58.9% |
About Dr. Veena Charu, M.D
Dr. Veena Charu, M.D is a Specialist healthcare provider based in Anaheim, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568438976.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Veena Charu, M.D has received a total of $454,847 in payments from pharmaceutical and medical device companies, with $1,687 received in 2024. These payments were reported across 736 transactions from 84 companies. The most common payment nature is "" ($385,743).
As a Medicare-enrolled provider, Charu has provided services to 15,011 Medicare beneficiaries, totaling 378,243 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 166 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Internal Medicine
- Location Anaheim, CA
- Active Since 02/24/2006
- Last Updated 06/03/2014
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1568438976
Products in Payments
- Revlimid (Drug) $6,985
- IMFINZI (Drug) $5,630
- Venclexta (Biological) $5,572
- TAGRISSO (Drug) $5,363
- Cabometyx (Drug) $3,718
- SYNDROS (Drug) $3,566
- Pomalyst (Drug) $2,806
- Ninlaro (Drug) $2,295
- CINVANTI (Drug) $2,026
- JEVTANA (Drug) $1,833
- Tecartus (Drug) $1,700
- Imbruvica (Drug) $1,681
- BRUKINSA (Drug) $1,492
- FOTIVDA (Drug) $1,451
- IMFINZI (Biological) $1,414
- Onivyde (Drug) $1,043
- IBRANCE (Drug) $1,003
- Kyprolis (Biological) $712.34
- DARZALEX (Biological) $388.28
- Lenvima (Drug) $359.68
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Anaheim
Dr. Peter Greaney, M.d, M.D
Specialist — Payments: $92,427
Specialist $92,427
Dr. Cheryl Effron, M.d, M.D
Specialist — Payments: $51,484
Specialist $51,484
Dennis Riff, M.d, M.D
Specialist — Payments: $39,787
Specialist $39,787
Mr. Ravi Makam, M.d, M.D
Specialist — Payments: $17,663
Specialist $17,663
Dr. Ajit Maniam, M.d, M.D
Specialist — Payments: $10,658
Specialist $10,658
Dr. Mahaveer Khemka, M.d, M.D
Specialist — Payments: $7,829
Specialist $7,829